September 2, 2022 01:28 PM EDT
Pharma
Marketing

Mer­ck spells out ac­cess, en­vi­ron­men­tal goals in lat­est ESG re­port

Nicole DeFeudis

Editor

Ac­cess is a key theme in Mer­ck’s lat­est en­vi­ron­men­tal, so­cial and gov­er­nance (ESG) progress re­port, as the phar­ma gi­ant touts a deal to pro­vide more …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

A service from the Financial Times